Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil

European Journal of Cancer

Volumn 45, Issue 5, 2009, Pages 890-898

  Ravizza, Raffaella ^a   Molteni, Roberta ^a   Gariboldi, Marzia B ^a   Marras, Emanuela ^a   Perletti, Gianpaolo ^a   Monti, Elena ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

5 Fluorouracil; Colon cancer; Drug resistance; Hypoxia; PMX290

Indexed keywords

FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PMX 290; PROTEIN INHIBITOR; THIOREDOXIN 1 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ASSAY; CELL HYPOXIA; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG POTENCY; DRUG RESISTANCE; DRUG SENSITIZATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPOXIA; MITOSIS INHIBITION; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RNA INTERFERENCE; TUMOR MODEL;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL HYPOXIA; CELL PROLIFERATION; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDOLES; NEOPLASM PROTEINS; SPHEROIDS, CELLULAR; SULFONES; THIOREDOXINS; TUMOR CELLS, CULTURED;

EID: 61349136245     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.12.021     Document Type: Article

References (52)

1. Harris A.L. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
2. Pouysségur J., Dayan F., and Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006) 437-443
3. Vaupel P., and Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26 (2007) 225-239
4. Trédan O., Galmarini C.M., Patel K., and Tannock I.F. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99 (2007) 1441-1454
5. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
6. Unruh A., Ressel A., Mohamed H.G., et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22 (2003) 3213-3220
7. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., and Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62 (2002) 3387-3394
8. Krishnamurthy P., Ross D.D., Nakanishi T., et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279 (2004) 24218-24225
9. Koshiji M., To K.K., Hammer S., et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol Cell 17 (2005) 793-803
10. Kulshreshtha R., Ferracin M., Wojcik S.E., et al. A microRNA signature of hypoxia. Mol Cell Biol 27 (2007) 1859-1867
11. Piret J.P., Minet E., Cosse J.P., et al. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem 280 (2005) 9336-9344
12. Erler J.T., Cawthorne C.J., Williams K.J., et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 24 (2004) 2875-2889
13. Semenza G.L. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12 (2007) 853-859
14. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26 (2007) 341-352
15. Welsh S.J., Williams R.R., Birmingham A., Newman D.J., Kirkpatrick D.L., and Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther 2 (2003) 235-243
16. Jones D.T., Pugh C.W., Wigfield S., Stevens M.F., and Harris A.L. Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation. Clin Cancer Res 12 (2006) 5384-5394
17. Nief N., Le Morvan V., and Robert J. Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel. Eur J Cancer 43 (2007) 955-962
18. Temmink O.H., Hoebe E.K., van der Born K., Ackland S.P., Fukushima M., and Peters G.J. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Brit J Cancer 96 (2007) 231-240
19. Bunz F., Hwang P.M., Torrance C., et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104 (1999) 263-269
20. Kaneda S., Takeishi K., Ayusawa D., Shimizu K., Seno T., and Altman S. Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res 15 (1987) 1259-1270
21. Mandola M.V., Stoehlmacher J., Zhang W., et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14 (2004) 319-327
22. Mariadason J.M., Arango D., Shi Q., et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63 (2003) 8791-8812
23. Cao Y., Li C.Y., Moeller B.J., et al. Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res 65 (2005) 5498-5505
24. Vordermark D., Shibata T., and Brown J.M. Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation. Neoplasia 3 (2001) 527-534
25. Kaidi A., Qualtrough D., Williams A.C., and Paraskeva C. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 66 (2006) 6683-6691
26. Carroll V.A., and Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66 (2006) 6264-6270
27. Osti D., Marras E., Ceriani I., et al. Comparative analysis of molecular strategies attenuating positional effects in lentiviral vectors carrying multiple genes. J Virol Methods 136 (2006) 93-101
28. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
29. Goethals L., Debucquoy A., Perneel C., et al. Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys 65 (2006) 246-254
30. Brown L.M., Cowen R.L., Debray C., et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 69 (2006) 411-418
31. Hussein D., Estlin E.J., Dive C., and Makin G.W. Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther 5 (2006) 2241-2250
32. Alvarez-Tejado M., Naranjo-Suarez S., Jiménez C., Carrera A.C., Landázuri M.O., and del Peso L. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J Biol Chem 276 (2001) 22368-22374
33. Fischer F., Baerenfaller K., and Jiricny J. 5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology 133 (2007) 1858-1868
34. Fujita H., Kato J., Horii J., et al. Decreased expression of hMLH1 correlates with reduced 5-fluorouracil-mediated apoptosis in colon cancer cells. Oncol Rep 18 (2007) 1129-1137
35. Koi M., Umar A., Chauhan D.P., et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54 (1994) 4308-4312
36. Robert J., Morvan V.L., Smith D., Pourquier P., and Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 54 (2005) 171-196
37. Maring J.G., Groen H.J., Wachters F.M., Uges D.R., and de Vries E.G. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 5 (2005) 226-243
38. Atkin G., Daley F.M., Bourne S., Glynne-Jones R., Northover J., and Wilson G.D. The effect of surgically induced ischaemia on gene expression in a colorectal cancer xenograft model. Brit J Cancer 94 (2006) 121-127
39. Griffiths L., Dachs G.U., Bicknell R., Harris A.L., and Stratford I.J. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 57 (1997) 570-572
40. Wei H., Wang C., and Chen L. Proliferating cell nuclear antigen, survivin, and CD34 expressions in pancreatic cancer and their correlation with hypoxia-inducible factor 1alpha. Pancreas 32 (2006) 159-163
41. Peng X.H., Karna P., Cao Z., Jiang B.H., Zhou M., and Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 281 (2006) 25903-25914
42. Zhang Q., Zhang Z.F., Rao J.Y., et al. Treatment with siRNA and antisense oligonucleotides targeted to HIF-1alpha induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer 111 (2004) 849-857
43. Sasabe E., Tatemoto Y., Li D., Yamamoto T., and Osaki T. Mechanism of HIF-1alpha-dependent suppression of hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer Sci 96 (2005) 394-402
44. Camps C., Buffa F.M., Colella S., et al. Hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14 (2008) 1340-1348
45. Baker A., Payne C.M., Briehl M.M., and Powis G. Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res 57 (1997) 5162-5167
46. Lillig C.H., and Holmgren A. Thioredoxin and related molecules - from biology to health and disease. Antioxid Redox Signal 9 (2007) 25-47
47. Huang L.E., Arany Z., Livingston D.M., and Bunn H.F. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271 (1996) 32253-32259
48. Welsh S.J., Bellamy W.T., Briehl M.M., and Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 62 (2002) 5089-5095
49. Kim W.J., Cho H., Lee S.W., Kim Y.J., and Kim K.W. Antisense-thioredoxin inhibits angiogenesis via pVHL-mediated hypoxia-inducible factor-1alpha degradation. Int J Oncol 26 (2005) 1049-1052
50. Carrero P., Okamoto K., Coumailleau P., O'Brien S., Tanaka H., and Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol Cell Biol 20 (2000) 402-415
51. Hirota K., Matsui M., Iwata S., Nishiyama A., Mori K., and Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 94 (1997) 3633-3638
52. Bradshaw T.D., Matthews C.S., Cookson J., et al. Elucidation of thioredoxin as a molecular target for antitumor quinols. Cancer Res 65 (2005) 3911-3919